The Norwegian Institute for Cancer Research organized a strategy seminar at Lysebu Hotel on March 9th for 84 participants. The first part of the program consisted of eight lectures on various strategy-related subjects. Four of the talks were given by external speakers. The second half of the meeting was devoted to group work. The participants were divided into eigth groups, discussing various subjects, followed up by a plenary session.
Institute director Erlend B. Smeland welcomes the audience to a day-long and inspiring strategy seminar at Lysebu Hotel.
Miceli R, Eriksson H, Lo Russo G, Alfieri S, Moksnes Bjaanæs M, Pietrantonio F, De Cecco L, Prelaj A, Proto C, Franzén J, McDonnell D, Berenguer Pina JJ, Beninato T, Mazzeo L, Giannatempo P, Verzoni E, Crown J, Helland Å, Eustace A(2024) Gender Difference in sidE eFfects of ImmuNotherapy: a possible clue to optimize cancEr tReatment (G-DEFINER): study protocol of an observational prospective multicenter study Acta Oncol, 63, 213-219 DOI 10.2340/1651-226X.2024.24179, PubMed 38647024
Fackler MJ, Pleas M, Li Y, Soni A, Xing D, Cope L, Ali S, Van Le Q, Van Nguyen C, Pham HT, Duong LM, Vanden Berg E, Wadee R, Michelow P, Chen WC, Joffe M, Fjeldbo CS, Lyng H, Sukumar S(2024) Discovery and technical validation of high-performance methylated DNA markers for the detection of cervical lesions at risk of malignant progression in low- and middle-income countries Clin Epigenetics, 16(1), 56 DOI 10.1186/s13148-024-01669-z, PubMed 38643219
Grindedal EM, Zucknick M, Stormorken A, Rønne E, Tandstad NM, Isaacs WB, Axcrona K, Mæhle L(2024) Outcomes of 10 years of PSA screening for prostate cancer in Norwegian men with Lynch syndrome Prostate(in press) DOI 10.1002/pros.24711, PubMed 38629217